Expression of DNA doublestrand repair proteins in oral leukoplakia and the risk of malignant transformation

Zhu,Minwen; Liu,Wei; Shi,Linjun; Xiao,Xuan; Wu,Wenyan; Wu,Lan; Zhou,Zengtong

doi:10.3892/ol.2018.8574

Expression of DNA doublestrand repair proteins in oral leukoplakia and the risk of malignant transformation

Authors:
- Minwen Zhu
- Wei Liu
- Linjun Shi
- Xuan Xiao
- Wenyan Wu
- Lan Wu
- Zengtong Zhou
View Affiliations

Affiliations: Department of Oral Mucosal Diseases, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, P.R. China, Department of Oral and Maxillofacial‑Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, P.R. China
Published online on: April 25, 2018 https://doi.org/10.3892/ol.2018.8574
Pages: 9827-9835
Copyright: © Zhu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study assessed the expression of the DNA doublestrand repair (DDR) proteins ATM serine/threonine kinase (ATM), checkpoint kinase 2 (CHEK2) and γH2A histone family member X (γH2AFX) in oral leukoplakia (OL) and evaluated their clinical significance and usefulness as biomarkers for predicting OL transformation. Retrospectively, ATM, CHEK2 and γH2AFX protein levels were evaluated using immunohistochemical analysis in 61 OL, 33 oral squamous cell carcinoma (OSCC) and 15 normal oral mucosa tissues. OL tissues were classified into two groups according to the epithelial dysplasia pathology: The low risk dysplasia group (n=41) and the high‑risk dysplasia group (n=20). The results of the present study revealed that the expression of ATM and γH2AFX in OSCC was significantly increased compared with that in OL with low‑risk dysplasia and normal oral mucosa tissues. There was no statistically significant difference in CHEK2 expression among the groups. ATM expression was correlated with that of γH2AFX in OSCC tissue. The prognostic values of the DDR proteins and their correlation with clinical and pathological parameters were evaluated further in 99 OL patients with low risk dysplasia. Multivariate analysis revealed that increased expression of ATM and γH2AFX was significantly associated with an increased risk of malignant transformation. Immunohistochemical analysis of ATM and γH2AFX protein expression provided useful prognostic information on the carcinogenesis of OL. Increased ATM and γH2AFX expression may indicate a poor prognosis.

View Figures

View References

1	Chi AC, Day TA and Neville BW: Oral cavity and oropharyngeal squamous cell carcinoma-an update. CA Cancer J Clin. 65:401–421. 2015. View Article : Google Scholar : PubMed/NCBI
2	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
3	Boy SC: Leukoplakia and erythroplakia of the oral mucosa-a brief overview. SADJ. 67:558–560. 2012.PubMed/NCBI
4	van der Waal I, Schepman KP, van der Meij EH and Smeele LE: Oral leukoplakia: A clinicopathological review. Oral Oncol. 33:291–301. 1997. View Article : Google Scholar : PubMed/NCBI
5	Khanna KK and Jackson SP: DNA doublestrand breaks: Signaling, repair and the cancer connection. Nat Genet. 27:247–254. 2001. View Article : Google Scholar : PubMed/NCBI
6	Peng A and Maller JL: Serine/threonine phosphatases in the DNA damage response and cancer. Oncogene. 29:5977–5988. 2010. View Article : Google Scholar : PubMed/NCBI
7	Bartkova J, Horejsi Z, Koed K, Krämer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, et al: DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 434:864–870. 2005. View Article : Google Scholar : PubMed/NCBI
8	Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, Venere M, Ditullio RA Jr, Kastrinakis NG, Levy B, et al: Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature. 434:907–913. 2005. View Article : Google Scholar : PubMed/NCBI
9	He Y, Chen Q and Li B: ATM in oral carcinogenesis: Association with clinicopathological features. J Cancer Res Clin Oncol. 134:1013–1020. 2008. View Article : Google Scholar : PubMed/NCBI
10	Raynaud CM, Hernandez J, Llorca FP, Nuciforo P, Mathieu MC, Commo F, Delaloge S, Sabatier L, André F and Soria JC: DNA damage repair and telomere length in normal breast, preneoplastic lesions, and invasive cancer. Am J Clin Oncol. 33:341–345. 2010. View Article : Google Scholar : PubMed/NCBI
11	Yuan J, Adamski R and Chen J: Focus on histone variant H2AFX: To be or not to be. FEBS Lett. 584:3717–3724. 2010. View Article : Google Scholar : PubMed/NCBI
12	Shiloh Y: ATM and related protein kinases: Safeguarding genome integrity. Nat Rev Cancer. 3:155–168. 2003. View Article : Google Scholar : PubMed/NCBI
13	Bartek J and Lukas J: Chk1 and CHEK2 kinases in checkpoint control and cancer. Cancer Cell. 3:421–429. 2003. View Article : Google Scholar : PubMed/NCBI
14	Zhou BB and Elledge SJ: The DNA damage response: Putting checkpoints in perspective. Nature. 408:433–439. 2000. View Article : Google Scholar : PubMed/NCBI
15	Peng CY, Graves PR, Thoma RS, Wu Z, Shaw AS and Piwnica-Worms H: Mitotic and G2 checkpoint control: Regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science. 277:1501–1505. 1997. View Article : Google Scholar : PubMed/NCBI
16	Chang CC, Hung CM, Yang YR, Lee MJ and Hsu YC: Sulforaphane induced cell cycle arrest in the G2/M phase via the blockade of cyclin B1/CDC2 in human ovarian cancer cells. J Ovarian Res. 6:412013. View Article : Google Scholar : PubMed/NCBI
17	Matthews TP, Jones AM and Collins I: Structure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapies. Expert Opin Drug Discov. 8:621–640. 2013. View Article : Google Scholar : PubMed/NCBI
18	Lantuejoul S, Raynaud C, Salameire D, Gazzeri S, Moro-Sibilot D, Soria JC, Brambilla C and Brambilla E: Telomere maintenance and DNA damage responses during lung carcinogenesis. Clin Cancer Res. 16:2979–2988. 2010. View Article : Google Scholar : PubMed/NCBI
19	Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, Solier S and Pommier Y: GammaH2AFX and cancer. Nat Rev Cancer. 8:957–967. 2008. View Article : Google Scholar : PubMed/NCBI
20	Rogakou EP, Boon C, Redon C and Bonner WM: Megabase chromatin domains involved in DNA doublestrand breaks in vivo. J Cell Biol. 146:905–916. 1999. View Article : Google Scholar : PubMed/NCBI
21	Warnakulasuriya S, Reibel J, Bouquot J and Dabelsteen E: Oral epithelial dysplasia classification systems: Predictive value, utility, weaknesses and scope for improvement. J Oral Pathol Med. 37:127–133. 2008. View Article : Google Scholar : PubMed/NCBI
22	Hu JL, Hu SS, Hou XX, Zhu X, Cao J, Jiang LH and Ge MH: Abnormal expression of DNA Double-Strand breaks related genes, ATM and GammaH2AFX, in thyroid carcinoma. Int J Endocrinol. 2015:1368102015. View Article : Google Scholar : PubMed/NCBI
23	Alkema NG, Tomar T, van der Zee AG, Everts M, Meersma GJ, Hollema H, de Jong S, van Vugt MA and Wisman GB: Checkpoint kinase 2 (Chek2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer. Gynecol Oncol. 133:591–598. 2014. View Article : Google Scholar : PubMed/NCBI
24	Bartkova J, Rezaei N, Liontos M, Karakaidos P, Kletsas D, Issaeva N, Vassiliou LV, Kolettas E, Niforou K, Zoumpourlis VC, et al: Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature. 444:633–637. 2006. View Article : Google Scholar : PubMed/NCBI
25	Wang YH, Li F, Luo B, Wang XH, Sun HC, Liu S, Cui YQ and Xu XX: A side population of cells from a human pancreatic carcinoma cell line harbors cancer stem cell characteristics. Neoplasma. 56:371–378. 2009. View Article : Google Scholar : PubMed/NCBI
26	Dou J, Wen P, Hu W, Li Y, Wu Y, Liu C, Zhao F, Hu K, Wang J, Jiang C, et al: Identifying tumor stem-like cells in mouse melanoma cell lines by analyzing the characteristics of side population cells. Cell Biol Int. 33:807–815. 2009. View Article : Google Scholar : PubMed/NCBI
27	Takahashi A and Ohnishi T: Does gammaH2AFX foci formation depend on the presence of DNA double strand breaks? Cancer Lett. 229:171–179. 2005. View Article : Google Scholar : PubMed/NCBI
28	Qiang L, Yang Y, Ma YJ, Chen FH, Zhang LB, Liu W, Qi Q, Lu N, Tao L, Wang XT, et al: Isolation and characterization of cancer stem like cells in human glioblastoma cell lines. Cancer Lett. 279:13–21. 2009. View Article : Google Scholar : PubMed/NCBI
29	Wasco MJ and Pu RT: Utility of antiphosphorylated H2AFX antibody (gamma-H2AFX) in diagnosing metastatic renal cell carcinoma. Appl Immunohistochem Mol Morphol. 16:349–356. 2008. View Article : Google Scholar : PubMed/NCBI
30	Mah LJ, El-Osta A and Karagiannis TC: GammaH2AFX as a molecular marker of aging and disease. Epigenetics. 5:129–136. 2010. View Article : Google Scholar : PubMed/NCBI
31	Matthaios D, Foukas PG, Kefala M, Hountis P, Trypsianis G, Panayiotides IG, Chatzaki E, Pantelidaki E, Bouros D, Karakitsos P and Kakolyris S: γ-H2AFX expression detected by immunohistochemistry correlates with prognosis in early operable non-small cell lung cancer. Onco Targets Ther. 5:309–314. 2012. View Article : Google Scholar : PubMed/NCBI
32	Oliveira-Costa JP, Oliveira LR, Zanetti R, Zanetti JS, da Silveira GG, Buim Chavichiolli ME, Zucoloto S, Ribeiro-Silva A and Soares FA: BRCA1 and γH2AFX as independent prognostic markers in oral squamous cell carcinoma. Oncoscience. 1:383–391. 2014. View Article : Google Scholar : PubMed/NCBI
33	Chou SJ and Alawi F: Expression of DNA damage response biomarkers during oral carcinogenesis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 111:346–353. 2011. View Article : Google Scholar : PubMed/NCBI
34	Inoue K, Fry EA and Taneja P: Recent progress in mouse models for tumor suppressor genes and its implications in human cancer. Clin Med Insights Oncol. 7:103–122. 2013. View Article : Google Scholar : PubMed/NCBI
35	Sullivan A, Yuille M, Repellin C, Reddy A, Reelfs O, Bell A, Dunne B, Gusterson BA, Osin P, Farrell PJ, et al: Concomitant inactivation of p53 and Chek2 in breast cancer. Oncogene. 21:1316–1324. 2002. View Article : Google Scholar : PubMed/NCBI
36	Zhang P, Wang J, Gao W, Yuan BZ, Rogers J and Reed E: CHEK2 kinase expression is down-regulated due to promoter methylation in non-small cell lung cancer. Mol Cancer. 3:142004. View Article : Google Scholar : PubMed/NCBI
37	Kilpivaara O, Bartkova J, Eerola H, Syrjäkoski K, Vahteristo P, Lukas J, Blomqvist C, Holli K, Heikkilä P, Sauter G, et al: Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients. Int J Cancer. 113:575–580. 2005. View Article : Google Scholar : PubMed/NCBI
38	Liu W, Wu L, Shen XM, Shi LJ, Zhang CP, Xu LQ and Zhou ZT: Expression patterns of cancer stem cell markers ALDH1 and CD133 correlate with a high risk of malignant transformation of oral leukoplakia. Int J Cancer. 132:868–874. 2013. View Article : Google Scholar : PubMed/NCBI
39	Liu W, Bao ZX, Shi LJ, Tang GY and Zhou ZT: Malignant transformation of oral epithelial dysplasia: Clinicopathological risk factors and outcome analysis in a retrospective cohort of 138 cases. Histopathology. 59:733–740. 2011. View Article : Google Scholar : PubMed/NCBI
40	Liu W, Wang YF, Zhou HW, Shi P, Zhou ZT and Tang GY: Malignant transformation of oral leukoplakia: A retrospective cohort study of 218 Chinese patients. BMC Cancer. 10:6852010. View Article : Google Scholar : PubMed/NCBI